(Reuters) – AstraZeneca said on Thursday its cancer drug Imfinzi in a late-stage trial failed to improve the chances of patients with locally advanced cervical cancer living without the disease worsening, when given along with chemoradiotherapy.
The results from the so-called “CALLA” trial compared the combination to chemoradiotherapy alone, and are a setback for AstraZeneca’s efforts to develop cancer therapies – a major area of focus for the drugmaker.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips)
